Events

Events

Webinar: Re-Writing the Genome

Combining Gene Editing and iPSC Technologies
for Preclinical Discovery and Translational Research

Watch our webinar on-demand to hear Ruby Chen-Tsai, Ph.D., CSO of Applied StemCell, discuss how her team is using genome engineering and iPSC technologies to advance disease modeling, lead compound discovery, and bioproduction.


You will learn about:

  • Using genome engineering technologies for the generation of preclinical research models
  • How genome editing technologies can be applied to the development of cell and gene therapies
  • Application of gene editing to bioproduction
  • CRISPR-mediated gene editing for the development of nucleic acid reference standards

About Our Speaker

Ruby Yanru Chen-Tsai, Ph.D. has worked on the development and modification of stem cells and pre-clinical models for over 25 years. Prior to Applied StemCell, Dr. Chen-Tsai was at Stanford University, where she served as Director of the Transgenic Research Center and Associate Director of the Stanford Cancer Institute. Dr. Chen-Tsai is a co-inventor of the TARGATT™ integrase technology and the “DICE” platform for site-specific gene insertion. Her current research focuses on pre-clinical model development, as well as gene- and stem cell-based therapies using genome editing technologies including CRISPR/Cas9 and TARGATT™ integrase.

ABOUT THE AUTHOR
author

Chandreyee Das

Senior Content Manager

Chandreyee Das, Ph.D. (Chemical Biology, UCSF) is a Senior Content Manager at Science Exchange with 15 years of research experience and 10 years of life science content marketing experience. Chandreyee was a Fulbright Scholar and won fellowships from the U.S. NSF and NIH. Following postdoctoral research at Dana-Farber Cancer Institute, she worked at MilliporeSigma, delivering scientific content to life science tools customers. She has published in both peer-reviewed and industry news outlets.

Leave a Reply

Your email address will not be published.